25. Onpattro

John Maraganore casual

Active ingredient: patisiran
Disease: peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis 
Peak sales estimate: $1 billion
Approved: Aug. 10
Company: Alnylam  

The scoop: The 16-year R&D quest to get Onpattro on the market, the first-ever approval for a small interfering ribonucleic acid, saw it gain a lot of love when it was approved in the summer: “Game-changing” and “a tremendous achievement” were just two of the glowing reviews from analysts, although maybe not from payers, given its $345,000-per-year price tag (after discounts, and a money-back guarantee if it doesn’t work). The so-called gene-silencing drug (here, Onpattro encases the siRNA into a lipid nanoparticle to deliver the drug directly into the liver, in an infusion treatment, to alter or halt the production of disease-causing proteins) is approved, also a first for the FDA, for patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). It can treat potentially up to 15,000 patients in the U.S. (although only around 20% are diagnosed), and there are around 50,000 patients worldwide. The biotech is eyeing blockbuster sales with the help of a big marketing push to get more patients diagnosed. But the FDA approved the drug for a smaller group of patients than investors had hoped, which hit its shares at the time and could hamper sales. And it was hit two months later by the approval of a rival drug in Ionis/Akcea’s Tegsedi, which is vying for the same patients. And Tegsedi is easier for those patients to take, given that it comes in a prefilled syringe, which patients can administer subcutaneously by themselves. In contrast, at the same annual list price, Alnylam’s Onpattro needs to be given intravenously by a trained medical professional once every three weeks. There could be even more competition in the near future in the shape of Pfizer’s tafamidis, a drug that wants to cover both ATTR and its sister disease, wild-type TTR, and could also include polyneuropathy. — Ben Adams 

25. Onpattro

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.